Late-stage clinical pharmaceutical company XORTX Therapeutics announced that an abstract on research sponsored by the company will be presented at the American Society of Nephrology (ASN) Kidney Week 2024 in late October. The study was conducted in the independent laboratory of Charles Edelstein, MD, PhD, at the University of Colorado.
Dr. Edelstein explained that “Xanthine oxidase in rats, mice and humans with polycystic kidney disease” describes results of mouse, rat, and human studies of polycystic kidney disease (PKD). The objective was to better understand serum xanthine oxidase (XO) activity in PKD at different disease stages and relate that activity to eGFR decline and total kidney volume.
Recent discoveries in rodent models of PKD point to overexpression or overactivity of XO, an essential enzyme within the uric acid pathway, but it is unclear whether XO overexpression or overactivity in humans is associated with PKD or more rapid disease progression. The new study sheds light on how increased serum uric acid or aberrant kidney tissue expression of XO may contribute to accelerate injury.
XORTX will provide a further update on the results during the first week of November.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.